Dianthus Therapeutics will discuss Phase 2 MaGic trial results for claseprubart in generalized Myasthenia Gravis on September 8, 2025.
Quiver AI Summary
Dianthus Therapeutics, Inc. has announced a conference call and webcast to discuss results from its Phase 2 MaGic trial of claseprubart (DNTH103) in treating generalized Myasthenia Gravis (gMG), scheduled for September 8, 2025, at 8:00 a.m. EDT. Participants can join the call by registering in advance to receive dial-in details, and the event will also be available via a live webcast on the company's website. Dianthus, based in New York City and Waltham, Massachusetts, is focused on developing advanced antibody complement therapeutics to address severe autoimmune diseases and aims to create innovative monoclonal antibodies with enhanced selectivity and potency.
Potential Positives
- Dianthus Therapeutics is scheduled to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103), indicating significant progress in their clinical development for treating generalized Myasthenia Gravis, a severe autoimmune disease.
- The upcoming conference call and webcast may enhance investor engagement and provide insights into the company's research progress, potentially boosting investor confidence.
- The company's focus on delivering next-generation antibody complement therapeutics positions it competitively within the biotechnology industry, emphasizing innovation in treatments for severe autoimmune and inflammatory diseases.
Potential Negatives
- Announcement of the conference call prior to the results of the Phase 2 trial could indicate uncertainty or anticipation of a volatile response from investors, raising concerns about the outcomes of the trial.
- Lack of detailed results from the Phase 2 MaGic trial in the press release may lead to speculation and uncertainty in the market about the drug's efficacy and safety profile.
FAQ
What is the purpose of the conference call on September 8, 2025?
The conference call will discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis.
How can I access the live webcast for the conference call?
The live webcast can be accessed through the Investors and Media section of Dianthus Therapeutics' website.
What should participants do to join the conference call?
Participants should pre-register to receive the dial-in number and personal PIN for the conference call.
What does Dianthus Therapeutics focus on?
Dianthus Therapeutics is dedicated to developing next-generation antibody complement therapeutics for severe autoimmune diseases.
Where can I find more information about Dianthus Therapeutics?
More information can be found on the company's website, www.dianthustx.com, and their LinkedIn page.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$DNTH Hedge Fund Activity
We have seen 48 institutional investors add shares of $DNTH stock to their portfolio, and 62 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP added 1,499,931 shares (+88.2%) to their portfolio in Q2 2025, for an estimated $27,943,714
- BAKER BROS. ADVISORS LP added 789,759 shares (+inf%) to their portfolio in Q2 2025, for an estimated $14,713,210
- VR ADVISER, LLC removed 744,373 shares (-42.7%) from their portfolio in Q2 2025, for an estimated $13,867,668
- JANUS HENDERSON GROUP PLC removed 683,616 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $12,735,766
- RTW INVESTMENTS, LP removed 666,667 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $12,093,339
- BRAIDWELL LP removed 375,355 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $6,992,863
- VANGUARD GROUP INC added 337,206 shares (+30.4%) to their portfolio in Q2 2025, for an estimated $6,282,147
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$DNTH Analyst Ratings
Wall Street analysts have issued reports on $DNTH in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 08/21/2025
- William Blair issued a "Outperform" rating on 07/02/2025
- Baird issued a "Outperform" rating on 05/13/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/13/2025
- Guggenheim issued a "Buy" rating on 03/12/2025
To track analyst ratings and price targets for $DNTH, check out Quiver Quantitative's $DNTH forecast page.
$DNTH Price Targets
Multiple analysts have issued price targets for $DNTH recently. We have seen 4 analysts offer price targets for $DNTH in the last 6 months, with a median target of $46.0.
Here are some recent targets:
- Laura Chico from Wedbush set a target price of $42.0 on 08/21/2025
- Joel Beatty from Baird set a target price of $50.0 on 05/13/2025
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $40.0 on 05/13/2025
- Yatin Suneja from Guggenheim set a target price of $84.0 on 03/12/2025
Full Release
NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced a conference call and webcast to discuss results from the Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) scheduled for tomorrow, Monday, September 8, 2025 at 8:00 a.m. EDT.
Investor Webcast & Conference Call Information
To access the live conference call by phone, please register
here
. Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN.
A live webcast may be accessed through the Investors and Media section of the Company’s website, www.dianthustx.com . Following the call, a replay will be available at the same location.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit www.dianthustx.com and follow us on LinkedIn .
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
[email protected]
